Pharmacy Benefit Managers · Pharmacy Benefit Manager · Regulatory action + Private litigation
CVS Caremark
Headline
The FTC's allegation is that the rebate system was not a discount mechanism at all but a pricing engine running backwards: insulin makers competed for preferred formulary placement based on how large a rebate they…
The FTC's allegation is that the rebate system was not a discount mechanism at all but a pricing engine running backwards: insulin makers competed for preferred formulary placement based on how large a rebate they offered off the LIST price, which gave everyone in the chain a reason to push list prices UP, with the PBM keeping a cut. Patients whose costs are calculated against list price - the uninsured, the underinsured, anyone in a deductible phase - paid the inflated number while the rebate went elsewhere. Caremark settled with the FTC in July 2026 on terms that lock in up to $8.5 billion in consumer savings over ten years, unlock up to $4.5 billion more through point-of-sale rebates, delink PBM fees from list prices, and cap member insulin out-of-pocket costs at $25 per claim for up to a 34-day supply ($50 and $75 for longer supplies) unless a plan sponsor opts out in writing. That the remedy is worth billions is the measure of what the practice was worth.
- Severity
- Evidence tierUnassigned
- Claims confirmed
- Last verified2026-08-04
Primary source. www.ftc.gov/terms/pharmacy-benefits-managers-pbm — Verified - primary source confirmed.
Terms
Arbitration
The three PBMs initially COUNTERSUED the FTC challenging the underlying lawsuit's validity; after a district court let the FTC case proceed, the PBMs took the challenge to the 8th Circuit Court of Appeals (which denied their bid to halt the FTC case), and the appeal was then DISMISSED on June 30, 2026 on the parties' joint stipulation, a voluntary dismissal, not a ruling, at a point when Express Scripts had settled (Feb 2026) and Caremark (March) and Optum Rx (June) had agreed to proposed settlements — illustrating that even a well-resourced industry coalition can find it more strategic to settle than to continue contesting an FTC antitrust action.
Data sharing
MAJOR FTC ANTITRUST ACTION (filed Sept 2024; Caremark settled via a proposed consent order announced July 14, 2026, final FTC approval not confirmed as of Oct 2026): the FTC sued the THREE LARGEST pharmacy benefit managers — Caremark (CVS), Express Scripts (Cigna), and OptumRx (UnitedHealth), which together handle roughly 80% of ALL US PRESCRIPTIONS (top 6 PBMs combined handle ~95%) — alleging they engaged in ANTICOMPETITIVE AND UNFAIR REBATING PRACTICES that ARTIFICIALLY INFLATED INSULIN PRICES, by preferring higher-list-price insulin products specifically because they generate bigger manufacturer REBATES for the PBM, even when cheaper insulin options exist. CVS Caremark and the FTC jointly moved (March 2026) to withdraw from adjudication to pursue a settlement, following the template set by Express Scripts' earlier settlement (see that row) — the FTC announced the Caremark settlement on July 14, 2026 as a proposed consent order put out for 30-day public comment (up to $8.5B in consumer savings over 10 years plus up to $4.5B in point-of-sale rebate savings).
Fees and billing
This case is DIRECTLY about drug PRICING/FEES — the entire allegation is that CVS Caremark's rebate structure made insulin more expensive than it needed to be for patients nationwide.
Contacts
Privacy contact. Not recorded.
Legal notice. Not verified this pass. If publicly traded: SEC Form 10-K cover page gives the official corporate address; the Secretary of State business-entity search in the state of incorporation gives the registered agent, which must accept service. If private: the state registered agent is usually the only reliable route.
Mailing address. Not recorded.
Evidence
| Claim | Kind | Support | Sources |
|---|---|---|---|
| 1. The FTC alleges insulin makers competed for preferred formulary placement based on rebates off the list price. | fact | supported | none recorded |
| 2. The rebate system pushed insulin list prices up. | fact | supported | none recorded |
| 3. The PBM kept a cut of the rebates. | fact | unknown | none recorded |
| 4. Patients whose costs are calculated against list price paid the inflated price while the rebate went elsewhere. | fact | unknown | 1 (1 confirmed) |
| 5. Caremark settled with the FTC in July 2026. | fact | supported | none recorded |
| 6. The settlement locks in up to $8.5 billion in consumer savings over ten years. | fact | unsupported | 1 (1 confirmed) |
| 7. The settlement unlocks up to $4.5 billion more through point-of-sale rebates. | fact | unsupported | 1 (1 confirmed) |
| 8. The settlement delinks PBM fees from list prices entirely. | fact | unsupported | 1 (0 confirmed) |
| 9. The settlement caps member insulin costs at $25 a month. | fact | unsupported | 1 (0 confirmed) |
| 10. The remedy's value measures what the practice was worth. | characterization | n/a | none recorded |
3 of 10 claims have a confirmed source of their own.
Sources
| Source | Claim | Tier | Status | Quote |
|---|---|---|---|---|
| regulator · 2026-07-14 www.ftc.gov/news-events/news/press-releases/2026/07/ftc-secures-major-settlement-caremark-resolving-antitrust-case-against-second-drug-middleman | Claim 4 | Unassigned | confirmed | “hurt patients whose out-of-pocket payments like copays and coinsurance are tied to the list price” Quote basis: not recorded. |
| regulator · 2026-07-14 www.ftc.gov/news-events/news/press-releases/2026/07/ftc-secures-major-settlement-caremark-resolving-antitrust-case-against-second-drug-middleman | Claim 6 | Unassigned | confirmed | “locks in place up to $8.5 billion in consumer savings over the next 10 years” Quote basis: not recorded. |
| regulator · 2026-07-14 www.ftc.gov/news-events/news/press-releases/2026/07/ftc-secures-major-settlement-caremark-resolving-antitrust-case-against-second-drug-middleman | Claim 7 | Unassigned | confirmed | “unlocks up to $4.5 billion in additional savings for patients over the same 10-year period from point-of-sale rebates.” Quote basis: not recorded. |
| regulator · 2026-07-14 www.ftc.gov/news-events/news/press-releases/2026/07/ftc-secures-major-settlement-caremark-resolving-antitrust-case-against-second-drug-middleman | Claim 8 | Unassigned | corrected | “delinks PBM fees from drug list prices” Quote basis: not recorded. |
| regulator · 2026-07 (p www.ftc.gov/system/files/ftc_gov/pdf/CaremarkandZinc-DecisionandOrder.pdf | Claim 9 | Unassigned | corrected | “$25 for a prescription claim with a 0-34 days' supply;” Quote basis: not recorded. |
Source vault
Link status: Candidate - not yet fetched
| Document | Last fetch | |
|---|---|---|
| Privacy policy caremark.com/wps/wcm/connect/privacy-policy | Not fetched yet | NO (HTML only) |
| Terms of service caremark.com/wps/wcm/connect/terms-of-use | Not fetched yet | NO (HTML only) |
| Website No URL recorded | Not fetched yet | — |
| Primary source https://www.ftc.gov/terms/pharmacy-benefits-managers-pbm Verification: Verified - primary source confirmed | Not fetched yet | — |
Enforcement
No enforcement actions are linked to this row.
State statute
No HQ state on file, so no state statute applies by headquarters.